Skip to Main Content

Nearly a dozen advocacy groups began a series of protests against Novartis this week for using “lies, threats and bribes” to pressure developing countries not to pursue measures to widen access to medicines.

The groups are targeting Novartis because the drug maker figures prominently in an intensifying effort by the U.S. Trade Representative and pharmaceutical industry trade groups to lean on the Colombian government to revamp its policies toward pricing and patents.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!